Paper Details

  1. Home
  2. Paper Details

Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.

Author: HarrisonSimon J, SlavinMonica A, TehBenjamin W, ThurskyKarin A, WorthLeon J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

The use of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) in patients with myeloma is associated with an increased risk of infection, particularly during maintenance therapy and relapse/refractory disease. Thalidomide was associated with the lowest risk of severe infection compared to other IMiDs. While IMiDs were associated with a reduced risk of infection during induction therapy for transplant-eligible patients, PI-based therapy did not show a significant difference compared to conventional therapy.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The objective of this review was to determine the impact of immunomodulatory drugs (IMiDs) and proteasome inhibitor (PI)-based therapy on infection risk in patients with myeloma across three treatment periods: induction, maintenance therapy and relapse/refractory disease (RRMM). METHODS...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejca.2016.07.025

データ提供：米国国立医学図書館（NLM）

Infection Risk in Multiple Myeloma: Navigating the Desert of Treatment

Multiple myeloma, a type of blood cancer, can be like a treacherous desert – it's full of challenges and potential dangers, one of which is infection. This study delved into the impact of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) on infection risk in patients with multiple myeloma, looking at different phases of treatment – induction, maintenance, and relapse/refractory disease.

A Complex Landscape of Infection Risk

The research found a complex landscape of infection risk across the different treatment phases. For instance, IMiDs seemed to reduce infection risk during induction therapy for transplant patients, but increased it during maintenance and relapse/refractory disease. It's like different parts of the desert have different dangers – some areas are more prone to sandstorms, while others have hidden traps.

Finding Safe Passage

Understanding the risks associated with different treatment phases is crucial for navigating this desert of disease. This study helps us identify the areas that need extra caution, like the oasis of thalidomide, which seemed to be associated with the lowest risk of severe infection. Knowing these risks allows us to choose the safest route and equip our patients with the tools they need to stay healthy.

Dr.Camel's Conclusion

This comprehensive review and meta-analysis sheds light on the complex relationship between multiple myeloma therapies and infection risk, highlighting the importance of personalized treatment strategies and careful monitoring. It's like finding a map to navigate the desert of multiple myeloma treatment, helping us to avoid the dangerous sandstorms of infection while ensuring the best possible outcome for our patients.
Date :
  1. Date Completed 2017-07-31
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

27592069

DOI: Digital Object Identifier

10.1016/j.ejca.2016.07.025

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.